Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19121120 | 0.79 | CTRC (0.31) | GRM5 | |
| SCHEMBL25310588 | 0.75 | AOC3 (0.39) | — | |
| SCHEMBL17662577 | 0.71 | NPC1 (0.36) | — | |
| SCHEMBL31321097 | 0.71 | NPC1 (0.33) | — | |
| SCHEMBL19122860 | 0.70 | ALDH1A1 (0.34) | — | |
| SCHEMBL4650783 | 0.69 | — | — | |
| SCHEMBL4491664 | 0.68 | TXNRD1 (0.50) | — | |
| SCHEMBL27175826 | 0.68 | CYP1A2 (0.38) | — | |
| SCHEMBL506237 | 0.67 | EED (0.46) | — | |
| SCHEMBL197752 | 0.66 | ITGB2 (0.36) | CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4508047-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119255988-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023198140-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | TP53 4264/4885CRHBP 128/4885RECQL 2831/4885 |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | TP53 3054/4885CRHBP 1237/4885RECQL 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.